Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy

被引：2
|
作者：
Cooper, Lauren B. [1 ,2 ]
Hernandez, Adrian F. [2 ]
机构：
[1] Inova Heart & Vasc Inst, Falls Church, VA USA
[2] Duke Univ, Med Ctr, Durham, NC USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷 / 08期
关键词：
HEART-FAILURE; HYPERKALEMIA; SPIRONOLACTONE; MORTALITY; ASSOCIATION;
D O I：
10.1002/ejhf.1221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1227 / 1229
页数：3
相关论文
共 50 条
  • [1] Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD Understanding and Mitigating the Risks
    Epstein, Murray
    Pecoits-Filho, Roberto
    Clase, Catherine M.
    Sood, Manish M.
    Kovesdy, Csaba P.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (03): : 455 - 457
  • [2] The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy
    Sica, Domenic A.
    CURRENT DRUG SAFETY, 2007, 2 (01) : 71 - 77
  • [3] Garbage in, garbage out: mitigating risks and maximizing benefits of AI in research
    Hanson, Brooks
    Stall, Shelley
    Cutcher-Gershenfeld, Joel
    Vrouwenvelder, Kristina
    Wirz, Christopher
    Rao, Yuhan
    Peng, Ge
    NATURE, 2023, 623 (7985) : 28 - 31
  • [4] Garbage in, garbage out: mitigating risks and maximizing benefits of AI in research
    Brooks Hanson
    Shelley Stall
    Joel Cutcher-Gershenfeld
    Kristina Vrouwenvelder
    Christopher Wirz
    Yuhan (Douglas) Rao
    Ge Peng
    Nature, 2023, 623 : 28 - 31
  • [5] Maximizing benefits and minimizing risks
    Sundarathiti, P
    Proceedings of the 8th Biennial Congress of the Asian & Oceanic Society of Regional Anesthesia and Pain Medicine, 2005, : 115 - 120
  • [6] Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy
    Roscioni, Sara S.
    de Zeeuw, Dick
    Bakker, Stephan J. L.
    Lambers Heerspink, Hiddo J.
    NATURE REVIEWS NEPHROLOGY, 2012, 8 (12) : 691 - 699
  • [7] Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy
    Sara S. Roscioni
    Dick de Zeeuw
    Stephan J. L. Bakker
    Hiddo J. Lambers Heerspink
    Nature Reviews Nephrology, 2012, 8 : 691 - 699
  • [8] Maximizing the Benefit and Mitigating the Risks of Moral Hazard
    Shaul, Randi Zlotnik
    Ungar, Wendy J.
    AMERICAN JOURNAL OF BIOETHICS, 2016, 16 (07): : 44 - 46
  • [9] ADRENAL VEIN SAMPLING WITHOUT DISCONTINUATION OF MINERALOCORTICOID RECEPTOR ANTAGONIST THERAPY
    Ganesh, Malini
    Abadin, Shabirhusain S.
    Fogelfeld, Leon
    ENDOCRINE PRACTICE, 2020, 26 (09) : 953 - 959
  • [10] Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
    Mai, Xurong
    Kometani, Mitsuhiro
    Yoneda, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
12345